Immune Response to Therapies

• 7741 · PDF AI设计的个性化新抗原疫苗EVX-01可在晚期黑色素瘤患者中诱导持久的从头T细胞反应 AI-designed personalized neoantigen vaccine, EVX-01, induces durable de novo T-cell responses in advanced melanoma patients Mads Lausen, Michail Angelos Pavlidis, Ohrt Andersen Rasmus, Thuesen Nikolas, Nadia Viborg, Georgina V. Long, Adnan Khattak, Paolo A Ascierto, Carolina Cimminiello, Thomas Trolle, Christian Garde, Michael J. Chisamore, Benjamin Wolthers, Stine Friis Thorsen, Birgitte Rønø, Daniela Kleine-Kohlbrecher
• 7742 · PDF 肿瘤内效应T细胞和巨噬细胞是转移性非小细胞肺癌(mNSCLC)PD-1轴阻断后长期生存的基础 Intratumoral effector T-cells and macrophages underlie prolonged survival after PD-1 axis blockade in metastatic non-small cell lung cancer (mNSCLC) Daniel Boiarsky, Thazin Nwe Aung, Anna Wurtz, Jianlei Gu, Benjamin Y. Lu, David L. Rimm, Arutha Kulasinghe, Katerina A. Politi, Scott Gettinger, Kurt Alex Schalper
• 7743 · PDF 预先存在的T细胞在溶瘤病毒疗法后驱动胶质母细胞瘤的持久抗肿瘤免疫 Pre-existing T cells drive durable anti-tumor immunity after oncolytic virus therapy in glioblastoma Maxime Meylan, Ye Tian, Lijian Wu, Alexander L. Ling, Daniel Kovarsky, Graham L. Barlow, Linh D. Nguyen, Jason Pyrdol, Lucas Westphal, Michel Julius, Nicolas L. Gonzalez Castro, Sydney D. Dumont, Andres Santos, Itay Tirosh, Mario L. Suva, E Antonio Chiocca, Kai W. Wucherpfennig
• 7744 · PDF 单细胞与空间图谱分析揭示NSCLC中新辅助抗PD-L1联合放化疗获得病理完全缓解背后的肿瘤-免疫特征 Single-cell and spatial profiling reveal tumor-immune features underlying pathologic complete response to neoadjuvant anti-PD-L1 and chemoradiotherapy in NSCLC Jii Bum (Joy) Lee, Sang Hoon Lee, Haangik Park, Seul Lee, Dong Kwon Kim, Jae-Hwan Kim, Ju-Hyeon Lee, Jaeho Cho, Chang Geol Lee, Chang Young Lee, Jin Gu Lee, Dae Joon Kim, Hyo Sup Shim, Sun Min Lim, Hye Ryun Kim, Byoung Chul Cho
• 7745 · PDF EGFR-TKI增强抗CD47抗体介导的巨噬细胞吞噬作用于EGFR突变型非小细胞肺癌 EGFR-TKI enhances anti-CD47 antibody-mediated macrophage phagocytosis in EGFR-mutant non-small cell lung cancer Myungja Ro, Seung Min Yang, Youngtaek Kim, Min-Hak Lee, Eun Ji Lee, JuHyeon Lee, Mi Ran Yun, Ji-Eun Park, Jiyea Choi, Hyesun Lee, Sung Ho Kim, Heung Tae Kim, Byoung Chul Cho
• 7746 · PDF CEACAM5/6+癌细胞和IL1B+巨噬细胞介导的抗PD-1治疗胃癌耐药机制 CEACAM5/6+ cancer cell and IL1B+ macrophage-mediated resistance in anti-PD-1 treated gastric cancer Liudeng Zhang, Jian Chen, Yikai Luo, Lie Wang, Han Liang
• 7747 · PDF retifanlimab联合抗LAG3/抗TIM3与retifanlimab单药治疗患者T细胞激活状态的比较 Comparison of T-cell activation status in patients treated with retifanlimab in combination with anti-LAG3/Anti-TIM3 vs retifanlimab alone Robert I. Haddad, Denis Soulières, Prakash Neupane, Amaury Daste, Zhiwan Dong, Jin Lu, Michelle Kinder, Jeff Jackson, Richard Schaub, Nawel Bourayou, John Janik, Christophe Le Tourneau
• 7748 · PDF 基于免疫相关RNA-seq生物标志物的聚类揭示转移性NSCLC中免疫治疗应答的异质性并指导亚型特异性策略 Immune-related RNA-seq biomarker-based clustering reveals heterogeneous immunotherapy responses and guides subtype-specific strategies in metastatic NSCLC Jiyon Lyu, Sebastià Franch-Expósito, Sanghwa Kim, Liam Il-Young Chung, Ronald Min, Sung Hwan Lee, Shinkyo Yoon, Michelle M. Stein, JACOB MERCER, Paul Fields, Bella Kim, Young Kwang Chae
• 7749 · PDF 高级别浆液性卵巢癌患者接受PARPi+ATRi联合治疗后免疫活性增强 Increased immune activity in patients with high-grade serious ovarian cancer after combination PARPi + ATRi therapy Elias Pavlatos, Benjamin Tate, Austin Nguyen, Ian S. Heller, Dimitrios Nasioudis, Janos L. Tanyi, Drew A. Torigian, Diego Rodriguez, Susan M. Domchek, Ronny I. Drapkin, Eric J. Brown, Gordon B. Mills, Fiona Simpkins
• 7750 · PDF 整合空间单细胞蛋白质组学与空间代谢组学揭示可预测黏膜黑色素瘤免疫治疗应答的肿瘤微环境 Integration of spatial single cell proteomics and spatial metabolomics reveals tumor microenvironment predictive of immunotherapy response in mucosal melanoma Jun Wang, Priyadharsini Nagarajan, Sungnam Cho, Yunhe Liu, Erin H. Seeley, Yibo Dai, Yang Liu, Jared K. Burks, Jennifer L. McQuade, Adi Diab, Linghua Wang, Suhendan Ekmekcioglu
• 7751 · PDF 整合多组学与空间转录组学揭示肝细胞癌的新型免疫治疗靶点 Integrative multi-omics and spatial transcriptomics reveal novel immunotherapy targets in hepatocellular carcinoma Zihui Zhao, Xiaohang Long, Siyuan HUANG, Yan Liu, Alfred S. l. Cheng
• 7752 · PDF 靶向SOAT1增强NK细胞介导的高级别浆液性卵巢癌细胞毒作用 Targeting SOAT1 to Boost NK Cell Mediated Cytotoxicity in High Grade Serous Ovarian Cancer Luqi Chen, Michelle K.y. Siu, Ruiqian Zhang, Ling Shan Hung, Mengyi Gu, Dickson Ngan, Xin He, Haonan Lu, Hextan Y.s. Ngan, Kui Liu, Annie Ny Cheung, Karen K.l. Chan
• 7753 · PDF 循环胸苷激酶活性（TKa）作为转移性非小细胞肺癌（NSCLC）的预测性和动态生物标志物：Immunoblood研究 Circulating thymidine kinase activity (TKa) as a predictive and dynamic biomarker in the metastatic non-small cell lung cancer (NSCLC): Immunoblood study Maristella Giammaruco, Lorenza Landi, Mattias Bergqvist, Gabriele Minuti, Silvia Carpano, Francesca Fusco, Martina Brandi, Fabiana Letizia Cecere, Vincenzo Pio Di Noia, Livia Tosetto, Andrea Torchia, Corrado Orciuolo, Daniele Marinelli, Grisel Maver Militello, Diana Giannarelli, Federico Cappuzzo
• 7754 · PDF 神经内分泌肿瘤中与肽受体放射性核素治疗相关的外周免疫特征 Peripheral immune signatures associated with peptide receptor radionuclide therapy in neuroendocrine tumors Eriko Katsuta, Takuto Nobuhiro, Masaru Takeuchi, Satoshi Matsui, Asano Daisuke, Ishikawa Yoshiya, Hiroki Ueda, Keiichi Akahoshi, Noritoshi Kobayashi, Yasushi Ichikawa, Daisuke Ban
• 7755 · PDF 通过理解髓系检查点作为T细胞检查点抑制剂耐药患者适应性耐药关键介导因素的作用而开发的癌症精准免疫疗法 Precision immune therapies for cancer developed through understanding the role of myeloid checkpoints as key mediators of adaptive resistance in T-cell checkpoint inhibitor resistant patients Rónán O'Hagan, Magali Perderzoli-Ribeil
• 7756 · PDF 一种肿瘤靶向IL-12免疫细胞因子疗法可增加晚期实体瘤患者外周中具有与增强肿瘤细胞裂解相关表型的自然杀伤（NK）细胞 A tumor-targeting IL-12 immunocytokine therapy increases peripheral natural killer (NK) cells with phenotypes associated with increased tumor cell lysis in patients with advanced solid tumors Stephanie C. Pitts, Nicole J. Toney, Jennifer L. Marte, James L. Gulley, Jeffrey Schlom, Renee N. Donahue
• 7757 · PDF 探究ICI诱导性结肠炎中调节性T细胞功能障碍的潜在机制 Investigating the mechanisms underlying regulatory T cell dysfunction in ICI-induced colitis Emily Schahrer, Paul Ngai, Mehdi Benjelloun Zahar, Christopher R. Weber, David Zemmour
• 7758 · PDF 基于细胞水平药效学介导药物处置模型预测晚期或转移性实体瘤患者中GI-102固定剂量给药和基于体重给药的药代动力学和药效学特征 Prediction of pharmacokinetics and pharmacodynamics profile for a fixed dosing and body weight-based dosing of GI-102 based on cell-level pharmacodynamics-mediated drug disposition model in patients with advanced or metastatic solid tumors Suemin Park, Seung Chan Choi, Kwang-Soo Shin, Nari Yun, Myoung Ho Jang, Hyeong-Seok Lim
• 7759 · PDF 构建一种新型免疫基因特征以区分免疫治疗应答者和无应答者 Construction of a novel immune gene signature to distinguish immunotherapy responders and non-responders Moonyoung Lee, Yona Kim, Sangjeong Ahn, Sung Hak Lee
• 7761 · PDF 三级淋巴样结构(TLS)代表性细胞在冷肿瘤中引发对抗PD-1联合治疗的应答 Tertiary lymphoid structure (TLS) representative cells elicit response to anti-PD-1 + therapy in a cold tumor Satish Sankaran, Priyanka Chevour, Kowshik Jaganathan, Biswajit Das, Moumita Nath, Abdul Haseeb, Jobin K Paul, Vasanthakumar A, Oliyarasi M, Rajashekar M, Jayaprakash C, Venkatesh T, MS Ganesh, Amritha Prabha, Prakash BV, Upendra K, Méhul Kapur, Ritu Malhotra, Govindaraj K, Pavithira ., Mohit Malhotra
• 7762 · PDF PD-L1依赖性的4-1BB共刺激作为单药或与tarlatamab联合使用可增强抗肿瘤疗效和T细胞持久性 PD-L1-dependent 4-1BB costimulation enhances anti-tumor efficacy and T cell persistence as monotherapy or in combination with tarlatamab Felipe Vences Catalan, Willy Tsai, Wendy Chen, Anja Henn, Kevin Cook, Maryam Yousefi, Tanya Vagner, Andrew Jimena, Khushboo Sharma, Deepali Sawant, Jason DeVoss, Matthias Friedrich, Mithun Khattar, Julie Bailis, Andrew Rankin, Sungeun Kim
• 7763 · PDF 卵巢癌中的FOXA1：治疗靶点与免疫治疗增强剂 FOXA1 in ovarian cancer: Therapeutic target and immunotherapy enhancer Taewan Kim, Baek MooJun, HyoWook Gil, Eunjung Yang, Kwangseock Kim, jaesung Ryu, Kong Hyejeong, Beamjun Park, Seob Jeon
• 7764 · PDF 在人源化免疫系统小鼠中模拟CRS Modeling CRS in humanized immune system mice Audrey Wetzel, Anaïs Meynet-Cordonnier, Clothilde Philouze, Charline Boulot, Emilie Bayon, Sebastien Tabruyn, Dan Georgess
• 7766 · PDF 可切除IA-IIIA期非N2 NSCLC中单剂量新辅助atezolizumab：来自PRINCEPS试验的肿瘤浸润分析 Single-dose neoadjuvant atezolizumab in resectable stage IA-IIIA non-N2 NSCLC: Tumor infiltrate analysis from the PRINCEPS trial Antonio Nuccio, Lydie Cassard, Nathalie Cozic, Malek Ben Salah, Vesna Lukic, Julien Adam, Wael Salem Zrafi, David Planchard, Jordi Remon, Pernelle Lavaud, Anas Gazzah, Vincent Thomas de Montpreville, Maria Rosa Ghigna, Patrick Dumont, Elie Fadel, Fabrice Barlesi, Caroline Caramella, Filippo Gustavo Dall’Olio, Olaf Mercier, Paul-Henry Cournède, Nathalie Chaput, Benjamin Besse
• 7767 · PDF 胶质母细胞瘤中溶瘤单纯疱疹病毒治疗后肿瘤免疫微环境的空间分析 Spatial profiling of the tumor immune microenvironment following oncolytic herpes simplex virus treatment in glioblastoma Sophia A. Paxton, Corinne H. Strawser, Lakshmi Prakruthi Rao Venkata, Elizabeth A. R. Garfinkle, James M. Markert, Katherine E. Miller, Kevin A. Cassady, Elaine R. Mardis
• 7768 · PDF 三阴性乳腺癌(TNBC)对新辅助化疗-免疫治疗应答的生物学通路 Biological pathways of response to neoadjuvant chemo-immunotherapy in triple-negative breast cancer (TNBC) Nickolas Stabellini, Prerana B. Parthasarathy, Iluja Gautam, Patricia A. Rayman, Monaben Patel, Paul G. Pavicic Jr, Adam Moen, Brian Race, Eden Mundell, Amanda Trevino, Jennifer Powers, Tyler Joseph Alban, Jennifer Ko, Bahar Moftakhar, Takae Mizukami, Cynthia Owusu, Timothy A. Chan, Alberto J. Montero, C. Marcela Diaz-Montero
• 7769 · PDF IL-12/抗PD-1装甲型溶瘤HSV-1重编程中枢神经系统免疫：MVR-C5252 PuMP试验中整合的纵向免疫、基因组和代谢CSF分析 IL-12/anti-PD-1 armored oncolytic HSV-1 reprograms CNS immunity: Integrated longitudinal immune, genomic, and metabolic CSF profiling in the MVR-C5252 PuMP Trial Elizabeth Owens, Kelly Hotchkiss, Stevie Threatt, Justin T. Low, Monika Anand, Julia Louw, Melody Goldston, Margaret O. Johnson, Claire Bradbury, James E. Herndon, Gerry A. Grant, David M. Ashley, Anoop P. Patel, Annik Desjardins, Michael C. Brown, Mustafa Khasraw

在会议检索中浏览本分会场